The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.

中文翻译：

---

多发性硬化症加重患者糖皮质激素治疗后尿路感染的评估

多发性硬化症加重的首个治疗方法通常是短期静脉注射甲基强的松龙（IVMP），有或没有口服泼尼松锥度（OPT）治疗方案。这项研究旨在评估IVMP和OPT与单独IVMP相比在复发性多发性硬化症患者中增加尿路感染（UTI）的风险和改善尿道症状的治疗效果。这项双盲随机临床试验是针对接受甲基强的松龙治疗5天的56例多发性硬化症复发患者进行的。将患者随机分为两组：口服泼尼松龙和安慰剂（逐渐减少20天）。分析了人口统计学数据，多发性硬化症的病程，尿路症状，扩展残疾状况量表（EDSS）评分和尿液数据。）。但是，干预组的尿路症状改善明显优于对照组（）。此外，IVMP后给予OPT不会增加多发性硬化症加重患者发生UTI的风险。尿液分析结果在基线和皮质类固醇渐减方案后均未显示任何差异。由于存在皮质类固醇感染的风险，因此不再需要对该组患者进行进一步的尿液筛查。